We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+6.45%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.23B
AUM Growth
+$1.54B
Cap. Flow
+$1.46B
Cap. Flow %
45.39%
Top 10 Hldgs %
68.77%
Holding
142
New
24
Increased
22
Reduced
20
Closed
25

Top Buys

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$1.32B
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$73.7M
3
SLRN
ACELYRIN
SLRN
+$37.2M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$21.3M
5
MORF
Morphic Holding, Inc. Common Stock
MORF
+$17M

Top Sells

Rank Stock Value
1
WW
WW International
WW
+$61.1M
2
ONC
BeOne Medicines Ltd
ONC
+$20.5M
3
FATE icon
Fate Therapeutics
FATE
+$14.8M
4
APLS
Apellis Pharmaceuticals
APLS
+$14.3M
5
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$13.1M

Sector Composition

Rank Sector Weight
1 Healthcare 54.66%
2 Consumer Discretionary 41.39%
3 Technology 0.24%
4 Financials 0.2%
5 Real Estate 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SEER icon
26
Seer Inc
SEER
$115M
$20.3M 0.63%
4,750,000
– –
VIGL
27
DELISTED
Vigil Neuroscience
VIGL
$18M 0.56%
1,911,191
-332,161
-15% -$3.14M
GERN icon
28
Geron
GERN
$911M
$17.9M 0.55%
5,565,889
– –
ROIV icon
29
Roivant Sciences
ROIV
$24.2B
$16.4M 0.51%
1,625,000
+1,025,000
+171% +$9.17M
GBIO
30
DELISTED
Generation Bio
GBIO
$15.5M 0.48%
281,419
– –
RLAY icon
31
Relay Therapeutics
RLAY
$3.98B
$15.2M 0.47%
1,213,725
-460,018
-27% -$5.72M
CBIO
32
Crescent Biopharma
CBIO
$598M
$14.9M 0.46%
85,891
– –
IMGN
33
DELISTED
Immunogen Inc
IMGN
$14.4M 0.45%
+765,497
New +$9.04M
OMGA
34
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$14.2M 0.44%
2,533,045
– –
PTGX icon
35
Protagonist Therapeutics
PTGX
$8.69B
$13.8M 0.43%
+500,000
New +$12.5M
VTYX
36
DELISTED
Ventyx Biosciences
VTYX
$13.4M 0.42%
408,519
-127,293
-24% -$4.39M
ERAS icon
37
Erasca
ERAS
$6.17B
$13M 0.4%
4,721,194
– –
ALPN
38
DELISTED
Alpine Immune Sciences Inc
ALPN
$12.3M 0.38%
1,193,030
– –
IMA
39
ImageneBio Inc
IMA
$64.2M
$12.1M 0.38%
154,126
+25,000
+19% +$1.79M
FHTX icon
40
Foghorn Therapeutics
FHTX
$287M
$12.1M 0.38%
1,720,720
– –
VRDN icon
41
Viridian Therapeutics
VRDN
$2.13B
$12M 0.37%
504,978
– –
REPL icon
42
Replimune Group
REPL
$405M
$11.6M 0.36%
500,000
– –
AMAM
43
DELISTED
Ambrx Biopharma Inc
AMAM
$11.6M 0.36%
702,291
– –
DHR icon
44
Danaher
DHR
$142B
$11.4M 0.35%
+53,580
New +$11.3M
NTLA icon
45
Intellia Therapeutics
NTLA
$1.49B
$11.3M 0.35%
276,077
– –
WVE icon
46
Wave Life Sciences
WVE
$1.13B
$10.4M 0.32%
2,870,523
-129,477
-4% -$523K
BDTX icon
47
Black Diamond Therapeutics
BDTX
$98.6M
$10.3M 0.32%
2,046,517
+400,000
+24% +$817K
RNAC icon
48
Cartesian Therapeutics
RNAC
$224M
$10.2M 0.32%
304,555
+141,782
+87% +$5.07M
MRSN
49
DELISTED
Mersana Therapeutics
MRSN
$9.97M 0.31%
121,182
+32,550
+37% +$4.76M
NTRA icon
50
Natera
NTRA
$35.9B
$9.73M 0.3%
200,000
– –
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2023 Portfolio in Review

As of Q2 2023, Artal Group held 142 positions worth $3.23B, up 92% from $1.68B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Artal Group deployed $1.46B of net new capital in Q2 2023, opening 24 new positions and adding to 22 existing holdings. Its largest new stake was CAVA Group: 32,007,990 shares worth $1.31B.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 94% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $20.5M trimmed.

  • Artal Group's largest Q2 2023 buy was CAVA Group: 32,007,990 shares worth $1.31B.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2023, an estimated $73.7M increase.
  • Artal Group's biggest Q2 2023 reduction was BeOne Medicines Ltd, cutting an estimated $20.5M.
  • Artal Group fully exited WW International in Q2 2023, selling an estimated $61.1M.
  • Artal Group's ten largest holdings make up 69% of its $3.23B portfolio in Q2 2023.
  • Artal Group opened 24 new positions and closed 25 in Q2 2023.
  • Artal Group's portfolio value rose 92% quarter-over-quarter to $3.23B.

Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.